Quarterly report · Q2
6095.TEDINET S100TEBI
Period2023-10-01 → 2024-03-31
Filed2024-05-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 48
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥7.9bn | 2023-10-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥14.5bn | 2022-10-01 → 2023-09-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥7.1bn | 2022-10-01 → 2023-03-31 | Cons. | Net sales |
| Operating income | ¥836m | 2023-10-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥717m | 2022-10-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥831m | 2023-10-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.2bn | 2022-10-01 → 2023-09-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥735m | 2022-10-01 → 2023-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥550m | 2023-10-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥735m | 2022-10-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥199m | 2023-10-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥618m | 2022-10-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥380m | 2022-10-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥213m | 2023-10-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥391m | 2022-10-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥14.9bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥15.2bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥14.5bn | at 2023-03-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥6.2bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥6.6bn | at 2023-09-30 | Cons. | Liabilities |
| Net assets / equity | ¥8.7bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥8.6bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥8.6bn | at 2023-03-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥5.8bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥5.4bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥5.8bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.4bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.7bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.1bn | at 2022-09-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥807m | 2023-10-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥600m | 2022-10-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥122m | 2022-10-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥47m | 2023-10-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥5.0bn | 2022-10-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥4.8bn | 2022-10-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥378m | 2023-10-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥3.7bn | 2022-10-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥4.2bn | 2022-10-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥9.18 | 2023-10-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-4.16 | 2024-01-01 → 2024-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥28.33 | 2022-10-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥17.42 | 2022-10-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥5.03 | 2023-01-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥27.99 | 2022-10-01 → 2023-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥17.05 | 2022-10-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 56.5% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 54.7% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.6% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 37
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-10-01 → 2024-03-31 | −¥434,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-10-01 → 2024-03-31 | −¥434,000 |
| Reconciling Itemsreconciling | segment profit | 2023-10-01 → 2024-03-31 | −¥685m |
| jpcrp040300-q2r_E30650-000Collective Intelligence Platformreportable segment | revenue | 2023-10-01 → 2024-03-31 | ¥6.4bn |
| jpcrp040300-q2r_E30650-000Collective Intelligence Platformreportable segment | revenue external | 2023-10-01 → 2024-03-31 | ¥6.4bn |
| jpcrp040300-q2r_E30650-000Collective Intelligence Platformreportable segment | revenue intersegment | 2023-10-01 → 2024-03-31 | ¥15,000 |
| jpcrp040300-q2r_E30650-000Collective Intelligence Platformreportable segment | segment profit | 2023-10-01 → 2024-03-31 | ¥1.5bn |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue | 2023-10-01 → 2024-03-31 | ¥234m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue external | 2023-10-01 → 2024-03-31 | ¥234m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | segment profit | 2023-10-01 → 2024-03-31 | −¥131m |
| jpcrp040300-q2r_E30650-000Preventive Healthcare Platformreportable segment | revenue | 2023-10-01 → 2024-03-31 | ¥1.2bn |
| jpcrp040300-q2r_E30650-000Preventive Healthcare Platformreportable segment | revenue external | 2023-10-01 → 2024-03-31 | ¥1.2bn |
| jpcrp040300-q2r_E30650-000Preventive Healthcare Platformreportable segment | revenue intersegment | 2023-10-01 → 2024-03-31 | ¥419,000 |
| jpcrp040300-q2r_E30650-000Preventive Healthcare Platformreportable segment | segment profit | 2023-10-01 → 2024-03-31 | ¥153m |
| —segment total | revenue | 2023-10-01 → 2024-03-31 | ¥7.9bn |
| —segment total | revenue external | 2023-10-01 → 2024-03-31 | ¥7.9bn |
| —segment total | revenue intersegment | 2023-10-01 → 2024-03-31 | ¥434,000 |
| —segment total | segment profit | 2023-10-01 → 2024-03-31 | ¥1.5bn |
| Reconciling Itemsreconciling | revenue | 2022-10-01 → 2023-03-31 | −¥5m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-10-01 → 2023-03-31 | −¥5m |
| Reconciling Itemsreconciling | segment profit | 2022-10-01 → 2023-03-31 | −¥657m |
| jpcrp040300-q2r_E30650-000Collective Intelligence Platformreportable segment | revenue | 2022-10-01 → 2023-03-31 | ¥5.7bn |
| jpcrp040300-q2r_E30650-000Collective Intelligence Platformreportable segment | revenue external | 2022-10-01 → 2023-03-31 | ¥5.7bn |
| jpcrp040300-q2r_E30650-000Collective Intelligence Platformreportable segment | revenue intersegment | 2022-10-01 → 2023-03-31 | ¥2m |
| jpcrp040300-q2r_E30650-000Collective Intelligence Platformreportable segment | segment profit | 2022-10-01 → 2023-03-31 | ¥1.3bn |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue | 2022-10-01 → 2023-03-31 | ¥243m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue external | 2022-10-01 → 2023-03-31 | ¥240m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue intersegment | 2022-10-01 → 2023-03-31 | ¥3m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | segment profit | 2022-10-01 → 2023-03-31 | −¥40m |
| jpcrp040300-q2r_E30650-000Preventive Healthcare Platformreportable segment | revenue | 2022-10-01 → 2023-03-31 | ¥1.2bn |
| jpcrp040300-q2r_E30650-000Preventive Healthcare Platformreportable segment | revenue external | 2022-10-01 → 2023-03-31 | ¥1.2bn |
| jpcrp040300-q2r_E30650-000Preventive Healthcare Platformreportable segment | revenue intersegment | 2022-10-01 → 2023-03-31 | ¥300,000 |
| jpcrp040300-q2r_E30650-000Preventive Healthcare Platformreportable segment | segment profit | 2022-10-01 → 2023-03-31 | ¥94m |
| —segment total | revenue | 2022-10-01 → 2023-03-31 | ¥7.1bn |
| —segment total | revenue external | 2022-10-01 → 2023-03-31 | ¥7.1bn |
| —segment total | revenue intersegment | 2022-10-01 → 2023-03-31 | ¥5m |
| —segment total | segment profit | 2022-10-01 → 2023-03-31 | ¥1.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 519
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)有限責任監査法人 トーマツ | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)滝沢 勝己 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)萬 政広 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior1YTDDuration | 7129040000 | JPY |
| Net sales (5-year summary) | CurrentYTDDuration | 7850221000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 14540835000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YTDDuration | 735082000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYTDDuration | 831274000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 1164252000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YTDDuration | 380411000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYTDDuration | 199278000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 617678000 | JPY |
| Comprehensive income (5-year summary) | Prior1YTDDuration | 389997000 | JPY |
| Comprehensive income (5-year summary) | CurrentYTDDuration | 212652000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 637826000 | JPY |
| Net assets (5-year summary) | Prior1QuarterInstant | 8639500000 | JPY |
| Net assets (5-year summary) | CurrentQuarterInstant | 8726222000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 8587296000 | JPY |
| Total assets (5-year summary) | Prior1QuarterInstant | 14479297000 | JPY |
| Total assets (5-year summary) | CurrentQuarterInstant | 14900928000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 15162163000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1YTDDuration | 17.42 | |
| Basic earnings loss per share (5-year summary) | CurrentYTDDuration | 9.18 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 28.33 | |
| Diluted earnings per share (5-year summary) | Prior1YTDDuration | 17.05 | |
| Diluted earnings per share (5-year summary) | CurrentYTDDuration | － | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | 27.99 | |
| Equity to asset ratio (5-year summary) | Prior1QuarterInstant | 0.576 | |
| Equity to asset ratio (5-year summary) | CurrentQuarterInstant | 0.565 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.547 | |
| Net cash provided by used in operating activities (5-year summary) | Prior1YTDDuration | 122311000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | CurrentYTDDuration | 806693000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration | 600073000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YTDDuration | -4796727000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | CurrentYTDDuration | -47413000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration | -5011980000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YTDDuration | 4243773000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | CurrentYTDDuration | -378394000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration | 3666316000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1QuarterInstant | 5708116000 | JPY |
| Cash and cash equivalents (5-year summary) | CurrentQuarterInstant | 5774053000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1YearInstant | 5393167000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1QuarterDuration | 5.03 | |
| Basic earnings loss per share (5-year summary) | CurrentQuarterDuration | -4.16 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 21986410 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 21986410 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 21986410 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 21986410 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |